Wellington Management Group LLP Grows Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS

Key Points

• Wellington Management increased its SELLAS Life Sciences stake by 73.2% in the second quarter, reaching 597,309 shares valued at approximately $8.8 million. Institutional ownership totaled 17.38% of the company.
• Analyst sentiment is mixed: two analysts rate SLS a Buy and one rates it a Sell, resulting in a consensus rating of Hold and an average price target of $10.
• SELLAS shares opened at $13.96, near their 12-month high of $15.88, while the company reported a quarterly loss of $0.05 per share, missing estimates by $0.01.

Wellington Management Group LLP grew its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 73.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 597,309 shares of the company's stock after acquiring an additional 252,531 shares during the period. Wellington Management Group LLP owned 0.30% of SELLAS Life Sciences Group worth $8,816,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp purchased a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $7,823,000. Dagco Inc. increased its holdings in SELLAS Life Sciences Group by 19.8% during the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company's stock worth $18,191,000 after purchasing an additional 203,653 shares during the period. Bank of America Corp DE raised its position in SELLAS Life Sciences Group by 535.7% during the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company's stock valued at $2,714,000 after purchasing an additional 540,748 shares in the last quarter. California State Teachers Retirement System raised its position in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of SELLAS Life Sciences Group by 20.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company's stock worth $193,000 after buying an additional 7,673 shares during the period. 17.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SLS shares. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $10.00.

SELLAS Life Sciences Group Trading Up 0.7%

Shares of NASDAQ SLS opened at $13.96 on Wednesday. The stock has a market capitalization of $2.82 billion, a PE ratio of -66.47 and a beta of 2.52. The stock's fifty day simple moving average is $12.80 and its two-hundred day simple moving average is $8.61. SELLAS Life Sciences Group, Inc. has a 12-month low of $1.39 and a 12-month high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.